Preventive Vaccines Market, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Other Vaccine Types), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), a

Preventive Vaccines Market, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Other Vaccine Types), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), and Other Disease Types), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Preventive vaccines protect people from serious and life-threatening infectious diseases. These vaccines help immune system fight infections faster and more effectively. Vaccines are one of the most effective ways to prevent serious disease in children and adults. Therefore, with the increase in prevalence of infectious diseases, the demand for preventive vaccines is also increasing with the rapid pace around the world.

Market Dynamics:

Increase in prevalence of several infectious diseases, increase in demand for vaccination, outbreak of COVID-19, rising initiatives to enhance R&D of vaccines, and increase in focus on the vaccine development are major factors expected to drive growth of the global preventive vaccines market during the forecast period.

For instance, the United States and Germany have been the largest investors in COVID-19 vaccine R&D, pouring around US$ 2 billion and US$ 1.5 billion into the effort, respectively. Pfizer and BioNTech, who developed the first COVID-19 vaccine authorized in the U.S., received around US$ 800 million in R&D funding. Moreover, in January 2022, Daiichi Sankyo Company, Limited announced that it has initiated a trial in Japan to investigate a booster dose of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19).

Key features of the study:

• This report provides in-depth analysis of the global preventive vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global preventive vaccines market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Sanofi SA, Pfizer Inc., Novavax Inc., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline PLC, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., AstraZeneca, and Takeda Pharmaceutical Company Limited, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global preventive vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preventive vaccines market.

• Global Preventive Vaccines Market By Vaccine Type:
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Other Vaccine Types
• Global Preventive Vaccines Market By Disease Type:
• Pneumococcal
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Other Disease Types
• Global Preventive Vaccines Market By Geography:
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America
• Company Profiles:
• Sanofi SA
• Pfizer Inc.
• Novavax Inc.
• Merck & Co. Inc.
• Johnson & Johnson
• GlaxoSmithKline PLC
• Daiichi Sankyo Co. Ltd.
• Emergent BioSolutions Inc.
• AstraZeneca
• Takeda Pharmaceutical Company Limited